Background: The pandemic of obesity and type2-diabetes mellitus has led to a increasing prevalence of Non Alcoholic Fatty Liver Disease (NAFLD) globally, including developing countries. The current epidemic of is reshaping the field of hepatology because patients with are at increased risk for not only liver-related morbidity and mortality but also cardiovascular disease. NAFLD also increases the ris of developing diabetes. ence patients with diabetes need to be screened for the presence of and vice versa. t is of paramount importance to differentiate between simple steatosis from on lcoholic teatohepatitis ( ) the later being more associated with hepatic as well as e tra hepatic complications.
INTroDucTIoN
NAFLD is a broad spectrum of diseases consisting of patients with simple steatosis or onalcoholic fatty liver, Non alcoholic steato hepatitis (NASH), NASH-related cirrhosis, and NASH-related HCC. n there is hepatic steatosis without significant in ammation.
is defined as steatosis and in ammation associated with the presence of one of the three additional features: ballooning of hepatocytes, Mallory hyaline, and fibrosis on liver histology.
is usually a histological diagnosis. t is very important to differentiate between and NASH to determine the prognosis, risk of progression, and for assessing the liver-related and cardiovascular morbidity and mortality which occurs more fre uently in patients with as and 3 in different studies. s lifestyles have become increasingly sedentary with obesity and type 2 diabetes mellitus pandemic, NAFLD is rapidly becoming the leading cause of chronic liver disease worldwide 4 . It is projected to be the principal etiology for liver transplantation within the ne t decade.
NAFLD is a risk factor for Type 2 Diabetes mellitus and cardiovascular disease
is associated not only with liver related morbidity and mortality but also with an increased risk of developing both cardiovascular disease and type 2 diabetes mellitus 5 . was a significant predictor for future diabetes in a Japanese middle-aged health check population especially in women. The relative ris of diabetes associated with fatty liver was . confidence interval ( ) 3.
. p . in men and . ( . 3 . p . ) in women 6 . urrent evidence shows that with resolution of fatty liver, there is a potential for decreasing risk of incident type 2 diabetes mellitus 7 .
is also significantly associated with a moderately increased cardiovascular disease risk among type 2 diabetic patients This risk is independent of other classical risk factors and only party e plained by the presence of metabolic syndrome ( ). n fact patients with are twice as li ely to die of cardiovascular disease than liver disease and liver disease is only the third leading cause of death in patients with following cardiovascular disease and malignancy 9 .
Type 2 Diabetes increases the risk of NAFLD progressions to more advanced liver disease
Type 2 diabetes mellitus is one of the strongest clinical predictors of the progression of NAFLD to NASH and cirrhosis (10) . The progression of NAFLD to NASH in non-diabetic individuals occurs in about of patients 11 . But the presence of Type 2 diabetes increases this ris of the progression by two to three fold 12 . The presence of diabetes also increased the risk for cirrhosis or hepatocellular carcinoma (HCC) among patients with . n fact Type diabetes has emerged as a significant predictor of worse outcomes in patients with 13 . There are data to demonstrate that HCC may occur in patients without cirrhosis 14, 15 . These data emphasi e the need to effectively diagnose and early in patients with obesity metabolic syndrome and type 2 diabetes mellitus
Diagnosis of NAFLD
The diagnostic criteria of NAFLD includes hepatic steatosis by either imaging or histology, no other causes of steatosis and no significant alcohol consumption . 16 ll individuals with metabolic ris factors should be screened with ultrasonography of the liver to identify liver fat and assessment of liver en ymes. owever ultrasonography is a relatively insensitive technique for detecting liver fat. The fatty infiltration must be at least 3 before ultrasonography will be able to diagnose hepatic steatosis. As an alternative, a simpler surrogate markers for diagnosing liver fat, such as the fatty liver inde (a composite score derived from waist circumference fasting triacylglycerol and glutamyltransferase T concentrations) can be used as a first line approach that also has an acceptable sensitivity and specificity for identifying liver fat 17 .
For diagnosis of NAFLD, other causes of steaosis should be e cluded including but not limited to increased alcohol consumption, viral hepatitis, surgical procedures, use of medications and total parenteral nutrition. There is a disagreement among different guidelines in defining the threshold for alcohol intake. According to EASL 17 significant alcohol consumption is defined as 3 g d in men and g d in women. The guidance considers standard drin per wee in men and in women as significant. sia acific Guidelines 19 defines significant alcohol inta e as standard alcoholic drin s wee ( g ethanol) in women and ( g) in men.
Components of the metabolic syndrome and diabetes should be screened. After making a diagnosis of the ne t step is assessment of fibrosis as the severity of fibrosis is the strongest predictor of liver-related outcome lthough histological e amination of the liver is the 'gold standard' to stage NAFLD severity, it is not a feasible option due to invasiveness of the test, complications, cost involved, and poor acceptability of the patients. epending on the results of these tests either follow up at 3-5 years or specialist referral for a decision as to whether to underta e a liver biopsy and or initiation of therapy. Alternatively, for NAFLD patients with mild abnormalities of non invasive fibrosis mar ers further follow up at years with repeat testing is advocated 20 . The EASL-EASDguidelines recommend that all patients with elevated LFTs because of NAFLD and advanced fibrosis should be referred to a hepatologist 20 .
Role of liver biopsy
iver biopsy should be reserved for the following conditions. patients who are at increased risk of having steato hepatitis and/or advanced fibrosis and in patients with suspected in whom competing etiologies for hepatic steatosis and the presence and or severity of coe isting s cannot be e cluded without a liver biopsy .
Treatment
ifestyle changes ifestyle modification including diet e ercise and weight loss has been recommended for treatment of patients with NAFLD. The recommendation is to give 500-1000 cal energy deficit diet to induce a weight loss of g wee with a total weight loss. ietary recommendation also involves e clusion of NAFLD-promoting components (processed food, and food and beverages high in added fructose. Weight loss has been reported to be associated with improvement in histologic features. min wee of moderate intensity aerobic physical activities in 3-5 sessions are generally preferred (bris wal ing stationery cycling) 17 . owever lifestyle modification is di cult to achieve and to sustain
Pharmacological treatment Whom to treat?
Drug therapy is indicated for progressive NASH (bridging fibrosis and cirrhosis) and early stage with increased ris of fibrosis progression (age years diabetes et increased T or active with high necroin ammatory activity 17 . 
Future pharmacological options of NASH
Gut microbiome is associated with increased gut permeability and transportation of gut metabolites and bacterial products into the portal circulation.
An increased lipopolysaccharide levels in the circulation occurs which binds to the monocyte differentiation antigen ( ) T R comple triggering an in ammatory reaction and insulin resistance. The gut microbiota is also involved in choline metabolism by converting it into to ic dimethylamine and trimethylamine which are transported to liver and converted into trimethylamine o ide (T ) that causes liver in ammation and damage 21 .
Changing the gut mocrobiota may be a treatment option in NAFLD. Solithromycin, a macrolide antibiotic with anti in ammatory properties was found to improve NASH in animal studies and is currently being studied in a phase 2 clinical trial 22 .
Antiobesity medications
rlistat is a gut lipase inhibitor which decreases the absorption of dietary fats. A small pilot study demonstrated reduction in hepatic steatosis associated with rlistat induced weight loss 23 .
owever it is not currently recommended as a treatment for NAFLD, but can be prescribed as an ad unct medication to help with weight loss in the NAFLD patients 24 .
Peroxisome proliferator-activator receptors (PPARs)
PPARs are nuclear receptors that bind fatty acids and fatty acid derivatives to regulate a number of metabolic processes. The three PPAR agonist considered for use in are lafibranor (dual R agonist) ioglita one ( R agonist) and aroglita ar (dual R agonist).
lafibranor has been shown to improve peripheral tissue insulin sensitivity and reduce alanine aminotransferase ( T) levels in patients with metabolic syndrome 25 . A phase 3 trial using elafibrinor versus placebo for wee s is currently ongoing for the treatment of NASH. (NCT02704403).
R agonists li e thia olidinediones are used in the treatment of diabetes and demonstrated to be effective in 26 . owever undesirable side effects and the possible need for long term therapy have limited widespread acceptance. aroglita ar is a dual R agonists which combines the beneficial effects of activating both R receptors. t has been shown to improve diabetic dyslipidemia 27 and is currently approved in India for this indication. A retrospective study of patients with dyslipidemia treated with saroglita ar for wee s demonstrated a significant decrease in T compared with baseline . A phase 3 trial is currently ongoing in India to assess the effect of saroglita ar versus placebo for wee s in biopsy proven noncirrhotic NASH (Clinical Trials Registry-India CTRI/2015/10/006236).
Farnesoid X receptor agonist
Bile acids can negatively regulate bile acid synthesis, decrease hepatic gluconeogenesis, and lipogenesis through interaction with their intracellular receptor the farnesoid X receptor (FXR).
A synthetic bile acid agonist of FXR, obeticholic acid ( ) was evaluated in a phase b clinical trial ( T) which included biopsy proven noncirrhotic patients who were randomi ed to mg day versus placebo for wee s 29 . This important study established the role of FXR in by showing that the XR bile acid agonist OCA improved histological features of NASH.
istological improvement with no worsening of fibrosis was demonstrated in a significant study participants on as compared to placebo ( vs .
). and decrease in fibrosis score was also significant. phase 3 trial to compare the effectiveness of versus placebo for noncirrhotic biopsy-proven NASH is currently ongoing ( T 3 ).
